$CAVA

Costanza Kelly sold $1.4M of CAVA

Costanza Kelly (Chief People Officer) sold 15,360 shares of CAVA GROUP, INC. (CAVA) at an average of $89.89 ($89.43–$90.00, $1.38M total) across 2 trades over 2026-06-15 to 2026-06-17.

Original reporting
SEC EDGAR · Costanza Kelly
Published Jun 17, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 11:35 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$CAVA
Neutral
medium confidence
Mentioned
$CAVA
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CAVANeutralLow
01

Why it matters

Insider selling can be a sentiment signal, but this filing alone does not provide new information about CAVA’s business performance, guidance, or strategy.

02

Market read

A new Form 4 reports an insider open-market sale of about $1.38M worth of CAVA shares over 2026-06-15 to 2026-06-17.

03

What to watch

No 10b5-1 plan is cited, so traders may over-interpret intent; also, the transaction size is meaningful in dollars but not clearly large relative to typical insider activity without additional context.

Relevance 6/10Novelty 5/10Timing: filed 2026-06-17, covering sales from 2026-06-15 to 2026-06-17

Background

The article is an SEC Form 4 insider transaction disclosure for CAVA Group, Inc.

Company-level read

Ticker impact

$CAVANeutralMedium confidence
Context

CAVA insider Costanza Kelly sold about 15,360 shares in open-market trades for roughly $1.38M, per a new SEC Form 4 filing.

Expected impact

Likely limited, short-lived sentiment impact; any move would be small unless paired with other company-specific catalysts.

Evidence & confidence

This is a routine Form 4 insider transaction with no 10b5-1 plan stated and no accompanying operational or guidance change in the text.

Market effects

No direct sector read-through; insider sales are company-specific and not a sector catalyst in the provided text.

None indicated.

None indicated.

Counterpoint

The sale may be unrelated to outlook (taxes, diversification, or personal liquidity), especially since the filing does not provide a stated reason.

Key entities

  • CAVA Group, Inc.

    Subject of the Form 4 insider sale disclosure.

  • Costanza Kelly

    Chief People Officer who sold shares in open-market transactions.

Related articles

$CAVAMed

Cava Founders and Board Accused of Insider Trading in $2.2 Billion Case: Report

A lawsuit reported by Bloomberg Law accuses Cava Group Inc. founders and board chair Ronald Shaich, plus financial backers, of insider trading. It alleges nearly $2.2 billion in stock sales from Aug 2024 to Mar 2025 while allegedly hiding slowing growth. Cava says the suit is without merit and will defend. Cava trades around $65.85 as of July 31.

$CAVAMed

Americans are skipping lettuce and salads as investigation into cyclospora outbreak continues

Federal officials are investigating a cyclospora outbreak linked to shredded iceberg lettuce supplied by Taylor Farms, with the CDC reporting at least 6,700 illnesses. Officials advised consumers to avoid certain Taylor Farms iceberg lettuce from Mexico, which the company recalled. Restaurant-chain shares fell, and Placer.ai data showed Taco Bell traffic down 30.9% Friday vs average this year; Taco Bell is owned by Yum Brands.

$CAVAMed

Why Is CAVA (CAVA) Stock Soaring Today

CAVA shares rose about 6.1% after Morgan Stanley upgraded CAVA to Overweight from Equalweight and raised its price target to $90, citing stronger fundamentals such as rising traffic, fast unit growth, and better visibility into margins. The move also coincided with a broader market lift after June CPI showed lower inflation.

$CAVAMed

CAVA is 'not a cheap stock.' Investors should buy it anyway, Morgan Stanley says

Morgan Stanley upgraded CAVA Group to overweight from equal-weight and raised its 12-month price target to $90 from $86, implying about 29% upside from Tuesday’s close. The firm said valuation is defensible despite the stock’s ~21% three-month drop tied to stagnant same-store sales growth. Analysts cited traffic, unit growth, and margin visibility. LSEG shows 17 of 29 analysts rate it buy/strong buy.